Top

Published in:

01-12-2009 | Original Article—Alimentary Tract

Significant association of RUNX3 T/A polymorphism at intron 3 (rs760805) with the risk of gastric atrophy in Helicobacter pylori seropositive Japanese

Authors: Asahi Hishida, Keitaro Matsuo, Yasuyuki Goto, Yoko Mitsuda, Mariko Naito, Kenji Wakai, Kazuo Tajima, Nobuyuki Hamajima

Published in: Journal of Gastroenterology | Issue 12/2009

Abstract

Background

This study aimed to examine the associations of a RUNX3 T/A polymorphism at exon 1 (Asn18Ile) (rs6672420) and another RUNX3 intronic T/A polymorphism (rs760805) with the risk of gastric cancer together with the risk of H. pylori seropositivity and gastric atrophy in Japanese people.

Methods

Study subjects were 583 histologically diagnosed gastric cancer patients and age- and sex-frequency-matched 1,742 control outpatients (among whom 1,637 subjects were eligible for the analyses), who visited Aichi Cancer Center Hospital from 2001 to 2005. Serum pepsinogens were measured to evaluate gastric atrophy.

Results

There was no significant association between the RUNX3 polymorphisms and the seropositivity. Among H. pylori seropositive subjects, we found a significant association between RUNX3 rs760805 polymorphism and the risk of gastric atrophy with the age- and sex-adjusted OR of 1.51 (95% CI 1.11–2.05, P = 0.008) in T/A, 1.59 (95% CI 1.08–2.33, P = 0.019) in A/A, and 1.53 (95% CI 1.14–2.05, P = 0.004) in T/A + A/A, compared with T/T genotype. We found no statistically significant associations between RUNX3 rs6672420 polymorphism and risk of gastric atrophy, nor between these two RUNX3 polymorphisms and the risk of gastric cancer relative to the subjects with gastric atrophy.

Conclusions

Our study results revealed that the RUNX3 intronic T/A polymorphism (rs760805) might modulate the risk of gastric atrophy among H. pylori seropositive subjects, and the RUNX3 T/A polymorphism at exon 1 (rs6672420) had little influence on the risks of H. pylori infection, gastric atrophy or gastric cancer in Japanese people. Further investigation is required to verify our findings.

Parkin DM, Whelan SL, Ferlay J, Raymond L, Young J. Cancer incidence in five continents, volume VII. Lyon: IARC Press; 1997.

Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer. 1999;80:827–41.CrossRefPubMed

Hamilton SR, Aaltonen LA. Pathology and genetics. Tumours of the digestive system. WHO Classification of Tumours. Lyon: IARC Press; 2000.

Tsuji S, Tsujii M, Murata H, Nishida T, Komori M, Yasumaru M, et al. Helicobacter pylori eradication to prevent gastric cancer: underlying molecular and cellular mechanisms. World J Gastroenterol. 2006;12:1671–80.PubMed

Danesh J. Helicobacter pylori infection and gastric cancer: systematic review of the epidemiological studies. Aliment Pharmacol Ther. 1999;13:851–6.CrossRefPubMed

Eslick GD, Lim LL, Byles JE, Xia HH, Talley NJ. Association of Helicobacter pylori infection with gastric carcinoma: a meta-analysis. Am J Gastroenterol. 1999;94:2373–9.CrossRefPubMed

Fukase K, Kato M, Kikuchi S, Inoue K, Uemura N, Okamoto S, et al. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. Lancet. 2008;372:392–7.CrossRefPubMed

Wong BC, Lam SK, Wong WM, Chen JS, Zheng TT, Feng RE, et al. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA. 2004;291:187–94.CrossRefPubMed

Tsuji S, Tsujii M, Kawano S, Hori M. Cyclooxygenase-2 upregulation as a perigenetic change in carcinogenesis. J Exp Clin Cancer Res. 2001;20:117–29.PubMed

10.

Yokozaki H, Kuniyasu H, Kitadai Y, Nishimura K, Todo H, Ayhan A, et al. p53 point mutations in primary human gastric carcinomas. J Cancer Res Clin Oncol. 1992;119:67–70.CrossRefPubMed

11.

Li QL, Ito K, Sakakura C, Fukamachi H, Inoue K, Chi XZ, et al. Causal relationship between the loss of RUNX3 expression and gastric cancer. Cell. 2002;109:113–24.CrossRefPubMed

12.

Oshimo Y, Oue N, Mitani Y, Nakayama H, Kitadai Y, Yoshida K, et al. Frequent loss of RUNX3 expression by promoter hypermethylation in gastric carcinoma. Pathobiology. 2004;71:137–43.CrossRefPubMed

13.

Fukamachi H, Ito K, Ito Y. Runx3-/- gastric epithelial cells differentiate into intestinal type cells. Biochem Biophys Res Commun. 2004;321:58–64.CrossRefPubMed

14.

Levanon D, Brenner O, Otto F, Groner Y. Runx3 knockouts and stomach cancer. EMBO Rep. 2003;4:560–4.CrossRefPubMed

15.

Zhang Z, Wang S, Wang M, Tong N, Fu G, Zhang Z. Genetic variants in RUNX3 and risk of bladder cancer: a haplotype-based analysis. Carcinogenesis. 2008;29:1973–8.CrossRefPubMed

16.

Tajima K, Hirose K, Inoue M, Takezaki T, Hamajima N, Kuroishi T. A model of practical cancer prevention for out-patients visiting a hospital: the hospital-based epidemiologic research program at Aichi Cancer Center (HERPACC). Asian Pac J Cancer Prev. 2000;1:35–47.PubMed

17.

Katoh M. Dysregulation of stem cell signaling network due to germline mutation, SNP, Helicobacter pylori infection, epigenetic change and genetic alteration in gastric cancer. Cancer Biol Ther. 2007;6:832–9.PubMedCrossRef

18.

Guilford P, Hopkins J, Harraway J, McLeod M, McLeod N, Harawira P, et al. E-cadherin germline mutations in familial gastric cancer. Nature. 1998;392:402–5.CrossRefPubMed

19.

Kim JH, Takahashi T, Chiba I, Park JG, Birrer MJ, Roh JK, et al. Occurrence of p53 gene abnormalities in gastric carcinoma tumorsand cell lines. J Natl Cancer Inst. 1991;83:938–43.CrossRefPubMed

20.

Tamura G, Kihana T, Nomura K, Terada M, Sugimura T, Hirohashi S. Detection of frequent p53 gene mutations in primary gastric cancer by cell sorting and polymerase chain reaction single-strand conformation polymorphism analysis. Cancer Res. 1991;51:3056–8.PubMed

21.

Park K, Kim SJ, Bang YJ, Park JG, Kim NK, Roberts AB, et al. Genetic changes in the transforming growth factor beta (TGF-beta) type II receptor gene in human gastric cancer cells: correlation with sensitivity to growth inhibition by TGFbeta. Proc Natl Acad Sci USA. 1994;91:8772–6.CrossRefPubMed

22.

Fukushige S, Matsubara K, Yoshida M, Sasaki M, Suzuki T, Semba K, et al. Localizationof a novel v-erbB-related gene, c-erbB-2, on human chromosome 17 and its amplification in a gastric cancer cell line. Mol Cell Biol. 1986;6:955–8.PubMed

23.

Rege-Cambrin G, Scaravaglio P, Carozzi F, Giordano S, Ponzetto C, Comoglio PM, et al. Karyotypic analysis of gastric carcinoma cell lines carrying an amplified c-met oncogene. Cancer Genet Cytogenet. 1992;64:170–3.CrossRefPubMed

24.

Sano T, Tsujino T, Yoshida K, Nakayama H, Haruma K, Ito H, et al. Frequent loss of heterozygosity on chromosomes 1q, 5q, and 17p in human gastric carcinomas. Cancer Res. 1991;51:2926–31.PubMed

25.

Uchino S, Tsuda H, Noguchi M, Yokota J, Terada M, Saito T, et al. Frequent loss of heterozygosity at the DCC locus in gastric cancer. Cancer Res. 1992;52:3099–102.PubMed

26.

Kuniyasu H, Yasui W, Yokozaki H, Akagi M, Akama Y, Kitahara K, et al. Frequent loss of heterozygosity of the long arm of chromosome 7 is closely associated with progression of human gastric carcinomas. Int J Cancer. 1994;59:597–600.CrossRefPubMed

27.

Crawford SE, Stellmach V, Murphy-Ullrich JE, Ribeiro SM, Lawler J, Hynes RO, et al. Thrombospondin-1 is a major activator of TGFβ1 in vivo. Cell. 1998;93:1159–70.CrossRefPubMed

28.

Hanai J, Chen LF, Kanno T, Ohtani-Fujita N, Kim WY, Guo WH, et al. Interaction and functional cooperation of PEBP2/CBF with Smads. Synergistic induction of the immunoglobulin germline Calpha promoter. J Biol Chem. 1999;274:31577–82.CrossRefPubMed

29.

Okuda T, van Dursen J, Hiebert SW, Grosweld G, Downing JR. AML1, the target of multiple chromosomal translocation in human leukemia, is essential for normal fetal liver hematopoiesis. Cell. 1996;84:321–30.CrossRefPubMed

30.

Look AT. Oncogenic transcription factors in the human acute leukemias. Science. 1997;278:1059–64.CrossRefPubMed

31.

Lee B, Thirunavukkarasu K, Zhou L, Pastore L, Baldini A, Hecht J, et al. Missense mutations abolishing DNA binding of the osteoblast-specific transcription factor OSF2/CBFA1 in cleidocranial dysplasia. Nat Genet. 1997;16:307–10.CrossRefPubMed

32.

Mundlos S, Otto F, Mundlos C, Mulliken JB, Aylsworth AS, Albright S, et al. Mutations involving the transcription factor CBFA1 cause cleidocranial dysplasia. Cell. 1997;89:773–9.CrossRefPubMed

33.

Ghozi MC, Bernstein Y, Negreanu V, Levanon D, Groner Y. Expression of the human acute myeloid leukemia gene AML1 is regulated by two promoter regions. Proc Natl Acad Sci USA. 1996;93:1935–40.CrossRefPubMed

34.

Bangsow C, Rubins N, Glusman G, Bernstein Y, Negreanu V, Goldenberg D, et al. The RUNX3 gene-sequence, structure and regulated expression. Gene. 2001;279:221–32.CrossRefPubMed

35.

Waki T, Tamura G, Sato M, Terashima M, Nishizuka S, Motoyama T. Promoter methylation status of DAP-kinase and RUNX3 genes in neoplastic and non-neoplastic gastric epithelia. Cancer Sci. 2003;94:360–64.CrossRefPubMed

36.

Kang GH, Lee HJ, Hwang KS, Lee S, Kim JH, Kim JS. Aberrant CpG island hypermethylation of chronic gastritis, in relation to aging, gender, intestinal metaplasia, and chronic inflammation. Am J Pathol. 2003;163:1551–6.PubMed

37.

Ito Y. Molecular basis of tissue-specific gene expression mediated by the runt domain transcription factor PEBP2/CBF. Genes Cells. 1999;4:685–96.CrossRefPubMed

38.

Ito Y. Oncogenic potential of the RUNX gene family: ‘overview’. Oncogene. 2004;23:4198–208.CrossRefPubMed

39.

Lund AH, van Lohuizen M. RUNX: a trilogy of cancer genes. Cancer Cell. 2002;1:213–5.CrossRefPubMed

40.

Miki K, Ichinose M, Shimizu A, Huang SC, Oka H, Furihata C, et al. Serum pepsinogens as a screening test of extensive chronic gastritis. Gastroenterol Jpn. 1987;22:133–41.PubMed

41.

Biemond I, Kreuning J, Jansen JB, Lamers CB. Serum pepsinogens in patients with gastric diseases or after gastric surgery. Scand J Gastroenterol. 1994;29:238–42.CrossRefPubMed

42.

Oksanen A, Sipponen P, Miettinen A, Sarna S, Rautelin H. Evaluation of blood tests to predict normal gastric mucosa. Scand J Gastroenterol. 2000;35:791–5.CrossRefPubMed

43.

Suzuki H, Hibi T, Marshall BJ. Helicobacter pylori: present status and future prospects in Japan. J Gastroenterol. 2007;42:1–15.CrossRefPubMed

44.

Sasazuki S, Inoue M, Iwasaki M, Otani T, Yamamoto S, Ikeda S, et al. Effect of Helicobacter pylori infection combined with CagA and pepsinogen status on gastric cancer development among Japanese men and women: a nested case–control study. Cancer Epidemiol Biomarkers Prev. 2006;15:1341–7.CrossRefPubMed

Title: Significant association of RUNX3 T/A polymorphism at intron 3 (rs760805) with the risk of gastric atrophy in Helicobacter pylori seropositive Japanese
Authors: Asahi Hishida
Keitaro Matsuo
Yasuyuki Goto
Yoko Mitsuda
Mariko Naito
Kenji Wakai
Kazuo Tajima
Nobuyuki Hamajima
Publication date: 01-12-2009
Publisher: Springer Japan
Published in: Journal of Gastroenterology / Issue 12/2009
Print ISSN: 0944-1174
Electronic ISSN: 1435-5922
DOI: https://doi.org/10.1007/s00535-009-0118-7

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 12/2009

Hepatocellular carcinoma arising from non-cirrhotic nonalcoholic steatohepatitis

Long-term outcome of endoscopic and/or percutaneous transhepatic therapy in patients with biliary stricture after orthotopic liver transplantation

A pilot trial of body weight reduction for nonalcoholic fatty liver disease with a home-based lifestyle modification intervention delivered in collaboration with interdisciplinary medical staff

Interleukin 10 inhibits interferon γ- and tumor necrosis factor α-stimulated activation of NADPH oxidase 1 in human colonic epithelial cells and the mouse colon

Retrospective analysis on the management of anticoagulants and antiplatelet agents for scheduled endoscopy

Clinical impact of radiotherapy for locally advanced pancreatic cancer

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials